Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
Open Access
- 1 September 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Osteoporosis Reports
- Vol. 8 (4), 178-184
- https://doi.org/10.1007/s11914-010-0027-y
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1Bone, 2010
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled TrialCalcified Tissue International, 2010
- Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2010
- Skeletal Consequences of Deletion of Steroid Receptor Coactivator-2/Transcription Intermediary Factor-2Published by Elsevier BV ,2009
- PPARγ2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cellsJournal of Cellular Biochemistry, 2008
- Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical StudiesPPAR Research, 2008
- Fat and Beyond: The Diverse Biology of PPARγAnnual Review of Biochemistry, 2008
- PPAR2 Regulates a Molecular Signature of Marrow Mesenchymal Stem CellsPPAR Research, 2007
- Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged BoneEndocrinology, 2007
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006